Login / Signup

Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers.

V ChungF J KosN HardwickY YuanJ ChaoD LiJ WaismanM LiK ZurcherP FrankelDon J Diamond
Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2018)
We have shown that the combination of p53MVA vaccine with pembrolizumab is feasible, safe, and may offer clinical benefit in select group of patients that should be identified through further studies.
Keyphrases
  • end stage renal disease
  • chronic kidney disease
  • ejection fraction
  • newly diagnosed
  • advanced non small cell lung cancer
  • peritoneal dialysis
  • prognostic factors
  • tyrosine kinase